Table II.
Treatment characteristics.
| Treatment | Radiotherapy group | Surgery group | ||
|---|---|---|---|---|
| n = 69 | % | n = 35 | % | |
| Induction chemotherapy | ||||
| Yes | 30 | 43.5 | 4 | 11.4 |
| FP | 5 | 16.7 | 3 | 75.0 |
| TPF | 24 | 80.0 | 1 | 25.0 |
| Carboplatin-cetuximab | 1 | 3.3 | 0 | 0 |
| None | 39 | 56.5 | 31 | 88.6 |
| Concomitant chemotherapy | ||||
| Yes | 51 | 73.9 | 19 | 54.3 |
| CDDP | 26 | 37.7 | 10 | 28.6 |
| Cetuximab | 15 | 21.7 | 3 | 8.6 |
| FP | 8 | 11.6 | 5 | 14.3 |
| Carboplatin | 2 | 2.9 | 1 | 2.9 |
| None | 18 | 26.1 | 16 | 45.7 |
| Radiotherapy | ||||
| Yes/dose (Gy)/Fr | 66 | 95.7 | 30 | 85.7 |
| 30/10 + 25/10 | 2 | 3.0 | 0 | 0 |
| 60-66/30-33 | 0 | 0 | 18 | 60.0 |
| 70/35 | 62 | 93.9 | 10 | 33.3 |
| Early stopping* | 2 | 3.1 | 2 | 6.7 |
| None | 0 | 0 | 5 | 14.3 |
| Planned but not made* | 3 | 4.3 | - | - |
| Radiation technique (n = 96) | n = 66 | n = 30 | ||
| VMAT | 8 | 12.1 | 0 | 0 |
| IMRT | 26 | 39.4 | 11 | 31.4 |
| 3D | 32 | 48.5 | 19 | 54.3 |
FP : 5-fluorouracil (800mg/m2 days 2-5) + cisplatin (80 mg/m2 day 1); TPF: docetaxel (75 mg/m2 day 1), cisplatin (75 mg/m2 day 1) and 5FU (750 mg/m2 days 2-5); CDDP: cisplatin; Cet: cetuximab; Gy: Grays; Fr: fractions; VMAT: volumetric modulated arc therapy; IMRT: intensity modulated radiotherapy; 3D: three dimensional radiotherapy
*: due to worsening of the general state and/or obvious progression.